Bausch + Lomb (NYSE:BLCO – Get Free Report)‘s stock had its “hold” rating reaffirmed by research analysts at Needham & ...

Bausch + Lomb (NYSE:BLCO – Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens ...

Bausch + Lomb (NYSE:BLCO; TSX:BLCO), a global leader in eye health products, has been making waves in the market with its recent financial performance and product launches. As the company ...

Good morning and welcome to Bausch + Lomb’s Third Quarter 2024 Earnings Call. [Operator Instructions] Please note this event ...

Bausch + Lomb (NYSE:BLCO; TSX:BLCO), a global leader in eye health products, has been making waves in the market with its recent financial performance and product launches. As the company navigates ...

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) today and set a price ...

Miebo and Xiidra, Bausch & Lomb's dry eye prescription therapies, contributed $150 million in collective sales and continue to grow nicely as insurance coverage expands. The firm also launched new ...

Bausch & Lomb is one of the largest vision care companies ... lens care solutions, and OTC eye care products. The US contact lens market is mainly controlled by four players—Johnson & Johnson ...

Bausch + Lomb scaled up its revenue guidance for the year after swinging to a profit in the latest quarter on the back of sales growth in each of its business segments.

Monday was an eventful day for Bausch + Lomb (NYSE: BLCO). The eye care specialist's major piece of internal news was that it earned its latest Food and Drug Administration (FDA) approval.